文献速递创伤骨科骨质疏松与代谢性骨病

瑞士骨折后诊疗现状及抗骨质疏松治疗预测因素:一项全国性健康索赔分析

Post-fracture care and predictors of anti-osteoporotic treatment in Switzerland: a nationwide health claims analysis.
PubMed 文献 · Osteoporos Int · 2026-01-12

这项回顾性队列研究利用瑞士最大健康保险机构的索赔数据,分析2021至2023年2458例椎体、6229例髋部及11314例非髋非椎体骨折患者。骨折后6个月内抗骨质疏松治疗率分别为髋部11.7%、椎体23%、其他骨折12.5%,88%髋部和77%椎体骨折患者未接受治疗。DXA检查、专科会诊和合并症负担是骨折后治疗的最强预测因素。

要点

  • 髋部骨折后6个月内88%患者未接受抗骨质疏松治疗,椎体骨折为77%。
  • 骨折后6个月治疗率:髋部11.7%、椎体23%、其他骨折12.5%。

核心结论

  • 髋部和椎体骨折后骨质疏松治疗率低,分别有88%和77%的患者在6个月内未接受治疗。
  • DXA检查、专科会诊和合并症负担是骨折后治疗的最强预测因素,提示可指导干预以缩小治疗差距的患者和系统层面关键因素。

研究设计与样本

  • 回顾性队列研究,使用瑞士最大健康保险机构的索赔数据,纳入2021至2023年年龄≥50岁、近期发生椎体、髋部或其他骨折的住院患者。
  • 按年龄和性别评估椎体、髋部和其他骨折的发病率,分析骨折后12个月抗骨质疏松治疗率及预测因素。
  • 描述各骨折部位的住院时长、相关费用和照护路径(养老院安置、康复、居家护理服务),以及骨折后12和24个月内的死亡率。

主要发现

  • 2021至2023年共发生2458例椎体骨折、6229例髋部骨折和11314例非髋非椎体骨折,女性分别占59%、70%和74%。
  • 8-11%的病例需要住院康复,18-21%的患者在骨折后3个月内新转入养老院。
  • 10%的髋部骨折和21%的椎体骨折患者在12个月内接受了DXA扫描。
  • 骨折后6个月内治疗率:髋部骨折11.7%(包括地舒单抗5.0%、唑来膦酸2.6%、阿仑膦酸钠2.1%),椎体骨折23%(包括地舒单抗9.4%、唑来膦酸4.7%、伊班膦酸3.6%、合成代谢药物2.7%),其他骨折12.5%。

关键数值与推荐

  • 髋部骨折后6个月内治疗率为11.7%,其中地舒单抗5.0%、唑来膦酸2.6%、阿仑膦酸钠2.1%。
  • 椎体骨折后6个月内治疗率为23%,其中地舒单抗9.4%、唑来膦酸4.7%、伊班膦酸3.6%、合成代谢药物2.7%。
  • 其他骨折后6个月内治疗率为12.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This retrospective study using Swiss health insurance claims data found that 88% of hip and 77% of vertebral fracture patients did not receive osteoporosis treatment within 6 months post-fracture. PURPOSE: The treatment gap in osteoporosis in Switzerland has previously been estimated at 83% based on T-scores and/or FRAX thresholds. However, real-world data on treatment rates following fractures remain limited. This study analysed treatment rates and their predictors in hospitalised patients aged ≥ 50 years with recent vertebral, hip or other fractures and the associated direct economic burden. METHODS: This retrospective cohort study utilised claims data from the largest Swiss health insurance provider. The incidence of vertebral, hip and other fractures was assessed by age and sex, and treatment rates and predictors of anti-osteoporotic therapies at 12 months post-fracture were analysed. Additionally, hospitalisation duration, associated costs and care trajectories (nursing home placement, rehabilitation, home care services) were described for each fracture site, as well as mortality within 12 and 24 months post-fracture. RESULTS: From 2021 to 2023, there were 2458 vertebral, 6229 hip and 11,314 non-hip, non-vertebral fractures (59%, 70% and 74% in women, respectively). Inpatient rehabilitation was required in 8-11% of cases, and 18-21% of patients newly transitioned to nursing home placement within 3 months post-fracture. DXA scans were performed within 12 months in 10% of hip and 21% of vertebral fracture patients and represented the strongest predictor of treatment initiation (odds ratio 10.2, 9.1-11.5), with female sex, older age and greater comorbidity showing weaker effects. Treatment rates within 6 months post-fracture were 11.7% for hip fractures (including 5.0% denosumab, 2.6% zoledronate, 2.1% alendronate), 23% for vertebral fractures (including 9.4% denosumab, 4.7% zoledronate, 3.6% ibandronate, 2.7% anabolic agents) and 12.5% for other fractures, with 8%, 13% and 11% of patients, respectively, already receiving osteoporosis therapy prior to the fracture. CONCLUSION: Osteoporosis treatment rates after hip and vertebral fractures were low, with 88% and 77% of patients, respectively, not receiving treatment within 6 months. DXA scans, specialist consultations and comorbidity burden were the strongest predictors of post-fracture treatment, highlighting key patient- and system-level factors that could guide interventions to close the treatment gap.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Everts-Graber J, Schmid G, Häuselmann H, et al. Post-fracture care and predictors of anti-osteoporotic treatment in Switzerland: a nationwide health claims analysis. Osteoporos Int. 2026. PMID: 41524786. doi:10.1007/s00198-025-07832-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。